<DOC>
	<DOCNO>NCT01303042</DOCNO>
	<brief_summary>Insulin therapy lispro mix 50/50 t.i.d . treatment single insulin device . The management comparatively simple easy , curative effect promising . It also report noninferiority observe basal/bolus therapy ( BBT ) prandial premixed therapy ( PPT , lispro mix 50/50 t.i.d. ) . The purpose study evaluate whether change insulin therapy BBT ( long-acting insulin bedtime plus mealtime rapid-acting insulin ) analog insulin therapy t.i.d . ( include therapy aspart mix 70/30 lispro mix 75/25 ) lispro mix 50/50 t.i.d . improve glycemic control patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Efficacy Insulin Lispro Mix 50/50 Therapy</brief_title>
	<detailed_description>Patients continue exist insulin therapy three month . After , investigator change insulin therapy accord insulin regimen continue therapy six month . Patients terminate sulfonylurea treatment change insulin therapy . The investigator change oral hypoglycemic agent whole study period . Regimen : Divide total unit insulin per day three equally apply amount mealtime injection insulin lispro mix 50/50 t.i.d . When unit indivisible remainder one unit , add mealtime injection breakfast . When remainder two unit , add unit mealtime injection breakfast dinner . Patients terminate trial HbA1c increase 1 % stay level three month change insulin regimen . When risk hypoglycemia change insulin regimen , investigator divide ninety percent total insulin unit per day three equally apply amount mealtime injection insulin lispro 50/50 . When consider safe , investigator increase insulin unit per day total insulin unit previous treatment within two month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Type 2 diabetes patient treated insulin basal/bolus therapy ( longacting insulin bedtime mealtime rapidacting insulin ) analog insulin therapy t.i.d . ( include therapy aspart mix 70/30 lispro mix 75/25 ) whose HbA1c 7.4 % . Patients renal failure serum creatinine level â‰§ 2.0 Patients hepatocirrhosis Patients proliferative diabetic retinopathy bad Patients acute infectious disease Patients treat steroids Patients cancer Pregnant patient Patients decide inappropriate subject study physician</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>insulin LISPRO</keyword>
	<keyword>Insulin therapy</keyword>
	<keyword>hemoglobin A1c protein , human</keyword>
	<keyword>Blood Glucose Self-Monitoring</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>1,5-Anhydroglucitol</keyword>
</DOC>